NexCAR19: India's First CAR-T Therapy Explained

NexCAR19 is India’s first approved CAR-T cell therapy. Its international non-proprietary name is talicabtagene autoleucel. It is an autologous, humanised, CD19-directed cell therapy made from a patient’s own T cells. ImmunoACT, a spin-off from IIT Bombay, developed it with Tata Memorial Hospital. India’s regulator approved it in October 2023.

That sentence carries a lot of weight for families who have been told, correctly, that CAR-T abroad costs several crore rupees. Until October 2023 there was no Indian product at all. NexCAR19 changed that, and the story behind it is a genuinely national one: laboratory work at IIT Bombay, clinical work at Tata Memorial Hospital, and manufacturing at ImmunoACT’s facility in Navi Mumbai.

CAR-T is not a drug in a vial. It is a living product built from the patient. T cells are collected from the blood, taken to a laboratory, given a new gene using a lentiviral vector so they display a chimeric antigen receptor on their surface, grown until there are enough of them, then returned to the same patient as one infusion. The receptor is aimed at CD19, a protein carried on the surface of B cells — including the cancerous ones in B-cell lymphoma and B-cell leukaemia.

One naming point causes confusion in search results. At approval the product was announced as actalycabtagene autoleucel. The international non-proprietary name later settled as talicabtagene autoleucel. Both names refer to the same product, and the manufacturer now uses the second.

NexCAR19 is approved in India for two groups of blood cancers only: relapsed or refractory B-cell non-Hodgkin lymphoma, and relapsed or refractory B-cell acute lymphoblastic leukaemia. Both are limited to patients aged 15 and above who have already had at least one line of treatment. It is not approved for solid tumours.

“Relapsed” means the cancer came back after treatment. “Refractory” means it did not respond to treatment in the first place. Both words describe a situation where standard options have already been tried, which is exactly the population this approval covers.

Two things sit outside that table and are worth stating plainly. First, CAR-T products are not interchangeable across diseases. Products aimed at BCMA are used in myeloma; NexCAR19 is aimed at CD19 and is not a myeloma treatment. Second, an approval that exists in the United States or Europe for a different CAR-T product is not an Indian approval for this one. The label that governs a prescription in India is the Indian label.

How the Indian product compares with the imported CAR-T therapies families read about — Kymriah, Yescarta and Carvykti — is set out in Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti.

The registration study of 64 patients, published in The Lancet Haematology, reported an overall response rate of 73% at the effective dose. A larger real-world study of 250 patients, published in Blood Cancer Journal in July 2026, reported 88% of the leukaemia group and about three-quarters of the lymphoma group responding within 28 days.

This is the part of the page where care matters most, because the numbers are easy to misread. They describe what happened to groups of patients who were studied. They are not a forecast for any one person, and they are not a reason on their own to choose or refuse this treatment.

How to read those numbers honestly

• A response is not a permanent result. Read down the table and you can see responses being lost between 28 days and 12 months. That is real, and any account of CAR-T that leaves it out is selling something.
• Roughly half the studied patients were free of progression at one year. That is a meaningful result in a group who had already exhausted standard options. It is also not everybody.
• These were selected patients. Everyone in the study met eligibility criteria for organ function, performance status and disease control. Someone who does not meet those criteria is not represented in the figures.
• There is no head-to-head trial against imported CAR-T products. Comparing percentages across separate studies with different patients is unreliable, and the manufacturer’s own framing is that outcomes are comparable to globally approved CAR-T therapies, not superior to them.
• Long-term data is still accumulating. The longest remission reported so far is 27 months. What happens at five and ten years is genuinely not yet known, for this product or for the class.

Response rates and progression figures quoted here are published study outcomes in the populations studied, as of August 2026. They are described, not promised. No page can tell you what your own result would be; only your haematologist, working from your reports, can discuss what is realistic in your situation.

The pathway has six stages: eligibility assessment, cell collection, manufacturing, lymphodepleting chemotherapy, one infusion, and monitored recovery. Manufacturing takes about 18 days. The infusion itself takes about 30 minutes. Almost all of the demanding part is what comes before and after it.

1. Eligibility assessment — a haematologist confirms the diagnosis is a CD19-positive B-cell cancer, checks the prior lines of therapy, and runs the organ-function and performance-status tests. Echocardiogram, kidney and liver blood tests, lung function and viral screening are part of this.
2. Slot scheduling and bridging — an apheresis slot is booked against manufacturing capacity. If the disease needs holding steady in the meantime, bridging treatment is planned around the timeline.
3. Leukapheresis — the cell collection. Blood is drawn through a machine that separates out the white cells and returns the rest. It takes roughly four to six hours in a certified apheresis unit, and the collected cells go to the manufacturing facility under controlled transport.
4. Manufacturing — about 18 days. The T cells are activated, the CAR gene is delivered using a lentiviral vector, the modified cells are grown to the treatment dose, then formulated, frozen and quality-checked. The manufacturer reports that more than 98% of commercial batches produced a usable product.
5. Lymphodepleting chemotherapy — a short course of chemotherapy over a few days before the infusion, to make room for the new cells. This is not optional and it has its own side effects.
6. The infusion — a single intravenous infusion of about 30 minutes. After months of preparation, the treatment itself is over in half an hour.
7. Monitored recovery — the reported median hospital stay after infusion was 8 days for the leukaemia group and 12 days for the lymphoma group. Fever, blood counts and neurological status are checked closely, and the family is asked to stay near the centre for a defined period after discharge.

The dose is worked out from body weight, not from a fixed vial size. The published efficacy threshold is more than 5 million CAR-T cells per kilogram. This is one reason CAR-T cannot be given at a day-care unit or an ordinary hospital ward.

The characteristic risks of any CAR-T therapy are cytokine release syndrome, neurological toxicity, and prolonged low blood counts with infection risk. In the published real-world study, severe cytokine release syndrome occurred in 6 to 7% of patients and severe neurological toxicity in 3 to 4%. Both are managed inside the treating centre, not at home.

Cytokine release syndrome is the immune system reacting hard as the modified cells go to work. It typically begins around day three after the infusion, which is why patients are kept in hospital. Fever is the usual first sign, and it can be followed by low blood pressure, breathlessness and a fast heart rate. In the published study, tocilizumab was needed in about half to two-thirds of patients, usually as a single dose.

Neurological toxicity, called ICANS, shows as confusion, difficulty finding words, tremor, drowsiness or, rarely, seizures. It is frightening to watch and it is usually reversible when caught early. Immune-effector-cell-associated haemophagocytic syndrome was reported in 18 to 23% of patients at any grade, and low blood counts of grade three or worse in about three-quarters within the first month, which is why infection precautions continue well after discharge.

Symptoms that need immediate hospital assessment after a CAR-T infusion, not home management: any fever of 38 °C or higher, breathlessness, chills or shaking, confusion or difficulty speaking, dizziness or fainting, a fast or irregular heartbeat, severe vomiting or diarrhoea, or unexplained collapse. Go to the treating centre’s emergency service straight away, and tell any doctor who sees you that CAR-T has been given — it changes how these symptoms are investigated.

Because CD19 sits on healthy B cells as well as cancerous ones, antibody levels can stay low for a long time afterwards, and some patients need immunoglobulin replacement. Vaccination timing after CAR-T is decided by the treating centre. Long-term effects, including fertility and any second-cancer risk after cell therapy, are areas where the evidence is still immature and honest uncertainty is the correct answer.

Published reporting in August 2026 put the price of NexCAR19 in India at under ₹30 lakh, described in that coverage as roughly one-tenth of CAR-T prices in Western countries, which are reported above 350,000 US dollars. It is delivered through accredited cell-therapy centres, not at ordinary hospitals. These figures are indicative, as of August 2026.

Even at a tenth of the global price, this is one of the largest single bills an Indian family will ever face, and the product price is not the whole bill. Leukapheresis, lymphodepleting chemotherapy, the hospital admission, intensive care if it is needed, supportive medicines such as tocilizumab, repeat scans, and travel and accommodation near the centre are all billed separately. Insurance treatment of cell therapy varies widely, and several policies cap or exclude it.

On availability: the manufacturer reports partnerships with more than 130 hospitals in India, over 800 patients treated through clinical and commercial use including international patients, and manufacturing capacity in the region of 1,200 patients a year. Access is therefore real but finite, and slots are scheduled.

The money question deserves its own page rather than a paragraph. What the components cost, what schemes and insurers have actually paid, and what families have done about the gap is covered in NexCAR19 Cost and How Families Pay for It.

If the real question behind your search is whether this applies to your own diagnosis, read Who Is Eligible for NexCAR19? next. It goes through the assessment in detail, including the tests that decide it and the reasons a referral is sometimes declined.

If the question is money, NexCAR19 Cost and How Families Pay for It breaks the bill into its parts and covers what insurance and schemes have and have not paid. If you are weighing the Indian product against the therapies you have read about abroad, Indian CAR-T vs Imported: Kymriah, Yescarta and Carvykti compares them on approval, target, availability and price.

For the wider view across checkpoint inhibitors, biosimilars and the other classes of immune treatment, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.